乙酰谷酰胺联合塞来昔布治疗高血压脑出血的疗效观察  

Therapeutic effect of aceglutamide combined with celecoxib on hypertensive cerebral hemorrhage

作　　者：肖燕 XIAO Yan(The First Hospital Affiliated to Henan University of Traditional Chinese Medicine,Zhengzhou 450000,China)

机构地区：[1]河南中医药大学第一附属医院,郑州450000

出　　处：《医药论坛杂志》2024年第13期1443-1446,共4页Journal of Medical Forum

摘　　要：目的探讨乙酰谷酰胺联合塞来昔布治疗高血压脑出血(hypertensive cerebral hemorrhage,HCH)的临床疗效。方法使用随机数表法将2023年1月—2024年1月在河南中医药大学第一附属医院就诊的66例HCH患者分为2组,各33例。在对照组接受乙酰谷酰胺治疗的基础上观察组加用塞来昔布。比较两组美国国立卫生研究院卒中量表(NIHSS)、改良Barthel指数(modified barthe-index,MBI)、中枢神经特异性蛋白(soluble protein-100β,S100β)、高迁移率族蛋白-1(high mobility group protein 1,HMGB1)、血清膜联蛋白AI(serum Annexin AI,ANXA1)、超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)、白介素-6(interleukin-6,IL-6)水平和不良反应发生率。结果治疗后,两组NIHSS评分均下降,且治疗后观察组NIHSS评分较低(P<0.05);治疗后,两组MBI评分均上升,且治疗后观察组MBI评分较高(P<0.05);治疗后,两组S100β、HMGB1水平均下降,而ANXA1水平均上升,且治疗后观察组S100β、HMGB1水平较低,而ANXA1水平较高(P<0.05);治疗后,两组hs-CRP、IL-6水平均下降,且观察组下降幅度较大(P<0.05);两组不良反应发生率(3.03%,3.03%)差异无统计学意义(P>0.05)。结论乙酰谷酰胺联合塞来昔布治疗可通过调节HCH患者炎症反应减轻其颅脑损伤,对加快患者神经功能、日常生活能力恢复有重要作用。Objective To investigate the clinical efficacy of aceglutamide combined with celecoxib in the treatment of hypertensive cerebral hemorrhage(HCH).Methods Totally 66 patients with HCH admitted to The First Hospital Affiliated to Henan University of Traditional Chinese Medicine from January 2023 to January 2024 were divided into 2 groups with 33 cases in each group by random number table method.The observation group was treated with celecoxib on the basis of aceglutamide in the control group.The levels of National Institute of Health stroke scale(NIHSS),modified Barthe-index(MBI).Soluble protein-100β(S100β),High mobility group protein 1(HMGB1),serum Annexin AI(ANXA1),Hypersensitive C-reactive protein(hs-CRP),Interleukin-6(IL-6)and the incidence of adverse reactions were compared.Results After treatment,NIHSS scores of both groups decreased,and NIHSS score of observation group was lower after treatment(P<0.05).After treatment,MBI scores of both groups increased,and MBI score of observation group was higher after treatment(P<0.05).After treatment,S100βand HMGB1 levels decreased,while ANXA1 levels increased in both groups.After treatment,S100βand HMGB1 levels were lower in observation group,while ANXA1 level was higher(P<0.05).After treatment,the levels of hs-CRP and IL-6 in both groups were decreased,and the decrease of observation group was large(P<0.05).The differences of the side effects between the two groups(3.03%,3.03%)were not statistically significant(P>0.05).Conclusion Aceglutamide combined with celecoxib can reduce craniocerebral injury in HCH patients by regulating inflammatory response,and play an important role in accelerating the recovery of neurological function and daily living ability.

关 键 词：高血压脑出血 乙酰谷酰胺 塞来昔布 神经功能 炎性因子 颅脑损伤 

分 类 号：R743.34[医药卫生—神经病学与精神病学]